Full-Time
Strategy and Corporate Development Director
Smith+Nephew
10,001+ employees
Global medical devices for orthopedics
No salary listed
Watford, UK
Hybrid
Hybrid working model for most professional roles.
Bachelor's, MBA
 Business & Strategy (1) |
|---|
Get referred to Smith+Nephew
See people who can refer or advise you
- At least 10 years of progressive experience in mergers and acquisitions, corporate development, or business development within healthcare, technology, or similarly complex industries is required.
- A strong track record of successfully executing transactions in a global, multi-divisional environment is required.
- Advanced financial acumen, including experience with complex deal structures, is required.
- The ability to lead negotiations and manage external partnerships is required.
- Strong analytical skills, including the ability to assess qualitative and quantitative business opportunities, are required.
- An established professional network across investment banking, consulting, or corporate development is required.
- A bachelor’s degree is required.
- Excellent communication and presentation skills, including the ability to influence senior stakeholders, are required.
- Strong interpersonal and relationship-building capabilities are required.
- The ability to operate independently and within teams is required.
- The ability to navigate complex and evolving deal processes is required.
- Identify, analyze, and develop opportunities for acquisitions, partnerships, and equity investments aligned with corporate strategy.
- Evaluate potential targets by conducting market and portfolio gap analyses.
- Lead end-to-end transaction execution, including due diligence, deal structuring, and negotiations.
- Build and maintain relationships with external partners, advisors, and stakeholders.
- Develop data-driven recommendations and present findings to senior leadership.
- Collaborate cross-functionally to support strategic initiatives and drive long-term growth.
- An MBA or other advanced degree is preferred.
- Experience in corporate development within a large company, venture capital, or private equity is desirable based on the preferred experience wording.
Smith+Nephew is a global medical technology company that designs and makes medical devices for orthopaedics, sports medicine, and advanced wound care. Its products help surgeons treat joints and soft tissues and support patient recovery, including knee repair systems, single-use negative pressure wound therapy devices, and other extremity orthopaedic products. These devices are used in hospitals and clinics to perform procedures and support healing, often after surgery or injury. The company differentiates itself with a broad, worldwide product portfolio and collaborations with healthcare organizations to improve care and efficiency for patients and providers. Its goal is to improve patient outcomes, streamline medical procedures, and expand access to advanced medical solutions around the world.
Company Size
10,001+
Company Stage
IPO
Headquarters
Watford, United Kingdom
Founded
1856
Get referred to Smith+Nephew
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 4 2026 H1 results still held trading profit, free cash flow, and ROIC guidance.
- July-August 2026 launches in CORI XT, FLOW FLEXTEND, and LYNX broaden commercial momentum.
- May 2026 buyback and January 2026 Integrity acquisition show capital discipline and portfolio depth.
What critics are saying
- August 4 2026 guidance cut to 4% revenue growth exposes weaker demand momentum.
- John Rogers leaves September 2026, removing financial continuity after the forecast reset.
- J&J's DePuy Synthes sale and VELYS expansion intensify orthopaedic competition through 2027.
What makes Smith+Nephew unique
- CORI XT and TESSA give Smith+Nephew owned robotics plus planning across joints.
- LEAF and RENASYS EDGE tie wound care to measurable hospital savings and compliance.
- Imperial College robotics center, launched August 17 2026, reinforces a durable innovation pipeline.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Holidays
Flexible Work Hours
Parental Leave
Fertility Treatment Support
Family Planning Benefits
Tuition Reimbursement
Wellness Program
Mental Health Support
Volunteer Time Off
Home Office Stipend
Phone/Internet Stipend
Discounted Stock Options
Health Savings Account/Flexible Spending Account
Employee Assistance Program
PTO/vacation?
Paid Sick Leave
Company News
Smith+Nephew has launched the FLOW FLEXTEND COBLATION Wand, a new radiofrequency resection device designed for complex hip procedures. The device features an adjustable-angle tip that provides enhanced joint access and tissue targeting in difficult-to-reach hip, knee, and shoulder anatomies. The wand incorporates Smith+Nephew's FLOW~IQ technology, which automatically balances saline outflow with COBLATION energy. Its design includes a precision electrode with an adjustable tip that improves access to targeted tissues whilst facilitating insertion and removal. The angle adjustment mechanism allows surgeons to set the desired position without continuous manual control. Early surgeon feedback has been positive, with users highlighting improved versatility in the central compartment and precise tissue preservation capabilities compared to existing instruments.
Smith+Nephew has launched ASC Solutions, an enterprise strategy designed to help ambulatory surgery centres optimise costs, improve quality and enhance performance. The initiative provides ASCs with access to clinical expertise, procedural technologies and data analytics to support growth and patient outcomes in value-based care settings. The company is expanding its ASC ONE delivery model into an integrated platform that simplifies centre development and accelerates facility readiness. ASC ONE coordinates services including facility design, construction, financing and clinical enablement through a single point of contact. Smith+Nephew has partnered with STERIS Unity Health Centers, Brasfield & Gorrie, Ghafari and Hopper Healthcare to provide expertise across the ASC lifecycle. The model enables physician-led organisations and health systems to streamline vendor management whilst reducing complexity and improving execution timelines.
Smith+Nephew has completed the first clinical cases using its next-generation CORI XT Handheld Robotics Platform for knee and shoulder arthroplasty. The platform is designed as a single handheld robotics system for various orthopaedic procedures, including partial to revision knee, hip, and anatomic and reverse shoulder surgeries. The first shoulder arthroplasty cases were performed at Duke Health by Dr Christopher Klifto, who used CORI SHOULDER Handheld Robotic Arthroplasty with the AETOS Shoulder System. Dr Bertrand Kaper subsequently completed the first CORI XT shoulder cases in an ambulatory surgery centre setting in Scottsdale, Arizona. The platform supports both hospital and ambulatory surgical centre environments, with a compact footprint tailored to different facility needs. Smith+Nephew's approach aims to enhance surgeon expertise whilst maintaining clinical control and workflow efficiency.
Smith+Nephew has launched the next generation LEAF Patient Monitoring System in the US, a pressure injury prevention platform designed to reduce hospital-acquired pressure injuries (HAPIs). The cloud-hosted system uses wearable sensors to monitor patient mobility and provide real-time turn status updates, improving workflow efficiency and protocol adherence. HAPIs cause approximately 60,000 annual deaths in the US and cost the economy $26.8 billion yearly. The LEAF system has demonstrated a 73% reduction in HAPI odds compared to standard care and delivers up to $1.8 million in estimated savings per critical care facility. The enhanced platform features an improved user interface developed with nursing teams and integrates seamlessly with hospital electronic medical records. It currently monitors over 150,000 patients annually across healthcare facilities.
Bernstein has cut its price target on Smith & Nephew to $31.85 from $36.20, maintaining a Market Perform rating. The adjustment followed the medical device company's fiscal Q1 trading update, which showed organic sales growth of 3.1%, missing the consensus estimate of 3.8%. Canaccord also reduced its price target to $30 from $32 the same day, keeping a Hold rating. Smith & Nephew reported Q1 revenue of $1.5 billion, with underlying revenue growth of 3.1% and reported growth of 6.6%, including a 350 basis point foreign exchange tailwind. The company develops and sells medical devices across three segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management.